The September changes to Australia's PBS will have a wide and lasting impact on the oncology treatment landscape.
Rachael Babin from the Oncology Network sits down with Professor Craig Underhill to translate the latest Australian Pharmaceutical Benefits Scheme (PBS) oncology and haematology listings into what clinicians actually need: who’s eligible, what the key trials show and what to watch for once the script is written.
This month we unpack three significant PBS developments:
We discuss the new multi-cancer listing for pembrolizumab, expanding access for patients with advanced or metastatic immunotherapy-sensitive cancers
The listing of enfortumab vedotin in combination with pembrolizumab for previously untreated advanced urothelial cancer
And the addition of durvalumab alongside FLOT chemotherapy as neoadjuvant and adjuvant treatment for resectable gastric and gastroesophageal junction cancers.
We discuss the clinical evidence behind these changes, some of the practical considerations around managing treatment-related toxicities and new funding to expand specialist prostate cancer nursing services.
If this helped you keep up with PBS oncology and haematology updates, please subscribe, share it with a colleague and leave a review so more clinicians can find us.
Visit the Show Notes for links to the papers and other materials related to the PBS updates discussed in this episode and to send us audio feedback or questions for future episodes.
Proudly produced by The Oncology Network - with thanks to our Editor, Graham Knowles.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Oncology Network. Innehållet i podden är skapat av The Oncology Network och inte av,
eller tillsammans med, Poddtoppen.
